

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/584,411
	Filing Date	5/31/00
	First Named Inventor	Shimkets
	Group Art Unit	1641
	Examiner Name	
	Attorney Docket Number	15966-552

15978 U.S. PTO
09/27/00
10/15/01

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
mg	A1	5916753	6/29/99	Ni, et al.			
↓	A2	5942400	8/24/99	Anderson, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
mg	B1	WO	98/36068-A2	Goli, et al.	8/20/98		
	B2	WO	98/07754-A1	Ni, et al.	2/26/98		
	B3	WO	99/46281-A2	Wood, et al.	9/16/99		
	B4	WO	99/31236-A2	Bougueleret, et al.	6/24/99		
	B5	WO	99/02456-A1	Leary, et al.	1/21/99		
	B6	DE	19813835-A1	Specht et al.	9/23/99		
	B7	WO	99/25825-A2	Bougueleret, et al.	5/27/99		
	B8	WO	99/32626-A1	Sims, J.E.	7/1/99		
	B9	WO	99/57132-A1	Jacobs, et al.	11/11/99		
	B10	WO	99/14328-A2	Wood, et al.	3/25/99		
	B11	WO	99/46380-A2	Tang, et al.	9/16/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
mg	C1	Cannella, B., et al. (1998). "The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis." <u>Proc Natl Acad Sci U S A</u> 95(17): 10100-5.
	C2	Gayle, M. A., et al. (1996). "Cloning of a putative ligand for the T1/ST2 receptor." <u>J Biol Chem</u> 271(10): 5784-9.
	C3	GenBank Accession Number ACC:CAA44652 (1991)
	C4	GenBank Accession Number ACC:CAA27525 (1986)
	C5	GenBank Accession Number ACC:BAA11680 (1996)
↓	C6	GenBank Accession Number ACC:BAA34488 (1998)

Murphy 10-26-04

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
my	C7	GenBank Accession Number ACC:L08825 (1993)
	C8	GenBank Accession Number ACC:CAA31302 (1988)
	C9	GenBank Accession Number ACC:A00281 (1989)
	C10	GenBank Accession Number ACC:CAA33109 (1989)
	C11	GenBank Accession Number ACC:CAA30372 (1988)
	C12	GenBank Accession Number ACC:CAA36809 (1990)
	C13	GenBank Accession Number ACC:P05307 (1987)
	C14	GenBank Accession Number ACC:P07237 (1987)
	C15	GenBank Accession Number ACC:P24347 (1990)
	C16	GenBank Accession Number ACC:CAA31343 (1988)
	C17	GenBank Accession Number ACC:X60933 (1991)
	C18	GenBank Accession Number ACC:X15059 (1989)
	C19	GenBank Accession Number ACC:X06220 (1986)
	C20	GenBank Accession Number ACC:Z18217 (1992)
	C21	GenBank Accession Number ACC:X63875 S41966 (1992)
	C22	GenBank Accession Number ACC:CAA40958 (1991)
	C23	GenBank Accession Number HSU19948 ACC:CAA31009 (1988)
	C24	GenBank Accession Number X68721 (1993)
	C25	GenBank Accession Number SPTREMBL-ACC:Q9Y3A6 (May, 1999)
	C26	Gladson, C. L. (1999). "The Extracellular Matrix of Gliomas: Modulation of Cell Function." <u>J Neuropathol Exp Neurol</u> 58(10): 1029-40.
	C27	Hoshino, K., et al. (1999). "The Absence of Interleukin 1 Receptor-related T1/ST2 Does Not Affect T Helper Cell Type 2 Development and Its Effector Function." <u>J Exp Med</u> 190(10): 1541-7.
	C28	Jahkola, T., et al. (1998). "Expression of Tenascin-C in Intraductal Carcinoma of Human Breast: Relationship to Invasion." <u>Eur J Cancer</u> 34(11): 1687-92.
	C29	Jahkola, T., et al. (1998). "Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence." <u>Br J Cancer</u> 78(11): 1507-13.
	C30	Lee, Y. H., et al. (1996). "The Expression of and Insulin Binding to Cellular Thyroid Hormone Binding Protein, but not Insulin Degrading Enzyme, is Increased During 3T3-L1 Adipocytes Differentiation." <u>Biochem Biophys Res Commun</u> 222(3): 839-43.
	C31	Notterpek, L. M. (1994). "A Protein Involved in Central Nervous System Myelination: Localization in the Extracellular Matrix and Induction in Neuroblastoma Cells." <u>Dev Neurosci</u> 16(5-6): 267-78.
	C32	Otaki, J. M. et al., (1999). "Neurestin: Putative Transmembrane Molecule Implicated in Neuronal Development." <u>Dev Biol</u> 212(1): 165-81.
	C33	Phillips, G. R., et al. (1998). "Domains of tenascin involved in glioma migration." <u>J Cell Sci</u> 111(Pt 8): 1095-104.
	C34	Treasurywala, S. et al., (1998). "Migration Arrest in Glioma Cells is Dependent on the Integrin Subunit." <u>Glia</u> 24(2): 236-43.
	C35	Vollmer, G., et al. (1992). "Down-Regulation of Tenascin Expression by Antiprogesterins during Terminal Differentiation of Rat Mammary Tumors." <u>Cancer Res</u> 52(17): 4642-8.
✓	C36	Wilson, K. E., et al. (1996). "Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours." <u>Br J Cancer</u> 74(7): 999-1004.

Misonk Y

10-26-04

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
my	C37	Yamauchi, K., et al. (1987). "Sequence of membrane-associated thyroid hormone binding protein from bovine liver: its identity with protein disulphide isomerase." <u>Biochem Biophys Res Commun</u> 146(3): 1485-92.
J	C38	Yu, D., et al. (1998). "Overexpression of ErbB2 Blocks Taxol-induced Apoptosis by Upregulation of p21 ^{Cip1} , which Inhibits p34 ^{Cdc2} kinase." <u>Mol Cell</u> 2(5): 581-91.
J	C39	GenBank Accession No. ACC::P71959 Hypothetical 9.9KD Protein CY441.31 - Mycobacterium Tuberculosis.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>Mish Y</i>	Date Considered	10-26-04
--------------------	---------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/584,411
	Filing Date	May 31, 2000
	First Named Inventor	Richard A. Shimkets
	Group Art Unit	1641
	Examiner Name	
	Attorney Docket Number	15966-552

10979 U.S. PTO
09/977418
10/15/01

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
m7	C40	Lai, et al., EMBL AF 151858 (1999).
	C41	Lai, et al., Genome Research 10(5):703-13 (2000).
I	C42	Vijayasaradhi, et al., J. Cell Biology 130(4):807-20 (1995).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>M. Smith</i>	Date Considered	10-26-04
---------------------------	-----------------	------------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.